{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:48:30Z","timestamp":1767134910667,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd006503.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2013,4,30]],"date-time":"2013-04-30T00:00:00Z","timestamp":1367280000000}}],"reference-count":35,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006503.pub3","type":"journal-article","created":{"date-parts":[[2013,4,27]],"date-time":"2013-04-27T23:07:04Z","timestamp":1367104024000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia"],"prefix":"10.1002","volume":"2013","author":[{"given":"Alessandro","family":"Squizzato","sequence":"first","affiliation":[{"name":"University of Insubria; Research Center on Thromboembolic Disorders and Antithrombotic Therapies, Department of Clinical and Experimental Medicine, School of Medicine; c\/o Medicina 1, Ospedale di Circolo viale Borri, 57 Varese Italy 21100"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Romualdi","sequence":"additional","affiliation":[{"name":"University of Insubria; Department of Clinical Medicine; viale Borri 57 Varese Italy 21100"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Passamonti","sequence":"additional","affiliation":[{"name":"Ospedale di Circolo e Fondazione Macchi; Division of Hematology, Department of Internal Medicine; Varese Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saskia","family":"Middeldorp","sequence":"additional","affiliation":[{"name":"Academic Medical Center; Department of Vascular Medicine; Meibergdreef 9 Amsterdam Netherlands 1105AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,4,30]]},"reference":[{"key":"10.1002\/14651858.CD006503.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythaemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006503.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1046\/j.1365-2141.1997.362682.x","article-title":"Low-dose aspirin in polycythaemia vera: a pilot study","volume":"97","author":"Gruppo Italiano Studio Policitemia Vera (GISP)","year":"1997","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD006503.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000204871","article-title":"Ticlopidine lowers plasma fibrinogen in patients with polycythaemia rubra vera and additional thrombotic risk factors","volume":"85","author":"Finelli","year":"1991","journal-title":"Acta Haematologica"},{"key":"10.1002\/14651858.CD006503.pub3-BIB0004|cit4","first-page":"172","article-title":"Adverse effects of antiaggregant platelet therapy in the treatment of polycythaemia vera","volume":"23","author":"Tartaglia","year":"1986","journal-title":"Seminars in Hematology"},{"key":"10.1002\/14651858.CD006503.pub3-BIB0005|cit5","unstructured":"Clopidogrel and Aspirin for the Treatment of Polycythemia Vera (ISCLAP). NCT00940784 http:\/\/clinicaltrials.gov"},{"key":"10.1002\/14651858.CD006503.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"e89S","DOI":"10.1378\/chest.11-2293","article-title":"Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"2 Suppl","author":"Eikelboom","year":"2012","journal-title":"Chest"},{"key":"10.1002\/14651858.CD006503.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","article-title":"Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia","volume":"116","author":"Alvarez-Larran","year":"2010","journal-title":"Blood"},{"key":"10.1002\/14651858.CD006503.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/ajh.2830470205","article-title":"Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935-1989","volume":"47","author":"Ania","year":"1994","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD006503.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"Antithrombotic Trialists' Collaboration","year":"2002","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD006503.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1182\/asheducation-2005.1.201","article-title":"Management of polycythaemia vera and essential thrombocythaemia","volume":"1","author":"Campbell","year":"2005","journal-title":"Hematology\/Education Program of the American Society of Hematology"},{"key":"10.1002\/14651858.CD006503.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.1990.8.3.556","article-title":"Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythaemia","volume":"8","author":"Cortelazzo","year":"1990","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006503.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythaemia and high risk of thrombosis","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006503.pub3-BIB0013|cit13","unstructured":"Deeks JJ Higgins JPT Altman DG (editors) Chapter 9: Analysing data and undertaking meta-analyses. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD006503.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD006503.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","article-title":"Acute leukaemia in polycythaemia vera: an analysis of 1638 patients enrolled in a prospective observational study","volume":"105","author":"Finazzi","year":"2005","journal-title":"Blood"},{"key":"10.1002\/14651858.CD006503.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/0003-4819-123-9-199511010-00003","article-title":"Polycythemia vera: the natural history of 1213 patients followed for 20 years","volume":"123","author":"Gruppo Italiano Studio Policitemia","year":"1995","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006503.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006503.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD006503.pub3-BIB0019|cit19","unstructured":"Higgins JPT Deeks JJ (editors) Chapter 7: Selecting studies and collecting data. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD006503.pub3-BIB0020|cit20","unstructured":"Higgins JPT Altman DG (editors) Chapter 8: Assessing risk of bias in included studies. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011"},{"key":"10.1002\/14651858.CD006503.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood.V80.8.1965.1965","article-title":"Increased thromboxane biosynthesis in patients with polycythaemia vera: evidence for aspirin-suppressible platelet activation in vivo","volume":"80","author":"Landolfi","year":"1992","journal-title":"Blood"},{"key":"10.1002\/14651858.CD006503.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1055\/s-2007-996124","article-title":"European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP): a randomised trial","volume":"23","author":"Landolfi","year":"1997","journal-title":"Seminars in Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD006503.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1136\/bmj.333.7568.597","article-title":"The case of the misleading funnel plot","volume":"333","author":"Lau","year":"2006","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD006503.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/aje\/126.2.161","article-title":"Misinterpretation and misuse of the kappa statistic","volume":"126","author":"Maclure","year":"1987","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD006503.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythaemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006503.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.0.CO;2-I","article-title":"Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976\u20131995","volume":"61","author":"Mesa","year":"1999","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD006503.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/MOH.0b013e3283439964","article-title":"Targeting myeloproliferative neoplasms with JAK inhibitors","volume":"18","author":"Pardanani","year":"2011","journal-title":"Curr Opin Hematol"},{"key":"10.1002\/14651858.CD006503.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD006503.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","article-title":"Life expectancy and prognostic factors for survival in patients with polycythaemia vera and essential thrombocythaemia","volume":"117","author":"Passamonti","year":"2004","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD006503.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"10.1002\/14651858.CD006503.pub3-BIB0031|cit31","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011"},{"key":"10.1002\/14651858.CD006503.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1055\/s-0038-1649916","article-title":"Increased thromboxane biosynthesis in essential thrombocythaemia","volume":"74","author":"Rocca","year":"1995","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD006503.pub3-BIB0033|cit33","unstructured":"Sterne JAC Egger M Moher D (editors) Chapter 10: Addressing reporting biases. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011"},{"key":"10.1002\/14651858.CD006503.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"10.1002\/14651858.CD006503.pub3-BIB0035|cit35","doi-asserted-by":"crossref","unstructured":"Squizzato A Romualdi E Middeldorp S Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia Cochrane Database of Systematic Reviews 2008 10.1002\/14651858.CD006503.pub2","DOI":"10.1002\/14651858.CD006503.pub2"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD006503.pub3\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T13:05:52Z","timestamp":1725455152000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006503.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Haematological Malignancies Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,4,30]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006503.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,30]]}}}